Pharma BD Deal Intelligence
A quiet, durable vertical-integration bolt-on: Beckman secured its key immunoassay input supplier, and the underlying franchise it fed grew steadily for a decade-plus with no signs of impairment or divestiture.
Full analysis, sources & comparables →Beckman Coulter pays $185M cash for long-time supplier Lumigen, projecting EPS-accretion by 2007 of at least $0.02/share.
Acquisition secures Beckman's chemiluminescent reagent pipeline; Lumigen had been a key Access supplier for over a decade.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Chemiluminescent diagnostics chemistry; key supplier to Beckman Access immunoassay
A quiet, durable vertical-integration bolt-on: Beckman secured its key immunoassay input supplier, and the underlying franchise it fed grew steadily for a decade-plus with no signs of impairment or divestiture.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Beckman Coulter Inc. / Lumigen Inc. (this deal) | 2006 | $185M | 69 |
| Beckman Coulter Inc. / Diagnostic Systems Laboratories Corporation (DSL) | 2005 | $138M | — |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Crucell N.V. / Berna Biotech AG | 2006 | $450M | 85 |
| Lonza Group AG / Cambrex Bioproducts and Biopharma businesses | 2006 | $460M | 83 |
| Reckitt Benckiser plc / Boots Healthcare International | 2006 | $3.4B | 82 |
| Genentech, Inc. (Roche Group) / Tanox Inc. | 2006 | $919M | 80 |
← Browse all deals · How we score deals
More: 2006 deals